Ad
related to: keppra xr duration of action in humans
Search results
Results from the WOW.Com Content Network
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset , myoclonic , or tonic–clonic seizures, [ 7 ] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein .
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]
Seletracetam (UCB 44212) is a pyrrolidone-derived [2] drug of the racetam family that is structurally related to levetiracetam (trade name Keppra). [ 2 ] [ 3 ] It was under development by UCB Pharmaceuticals as a more potent and effective anticonvulsant drug to replace levetiracetam but its development has been halted.
In February 2019, 38-year-old Michael Cochran died suddenly. Prosecutors said his wife Natalie Cochran poisoned him with insulin to conceal her over $2 million Ponzi scheme, which she operated ...
Its precise mechanism of action was unknown at the time of approval, and the exact amino acid targets involved remain uncertain to this day. [ 16 ] The U.S. Food and Drug Administration (FDA) accepted UCB's New Drug Application for lacosamide as of November 29, 2007, beginning the approval process for the drug.
There is no universally accepted mechanism of action for racetams. Racetams generally show negligible affinity for common central nervous system receptors , but modulation of central neurotransmitters , including acetylcholine and glutamate , has been reported.
Carbamazepine, sold under the brand name Tegretol among others, is an anticonvulsant medication used in the treatment of epilepsy and neuropathic pain. [4] [1] It is used as an adjunctive treatment in schizophrenia along with other medications and as a second-line agent in bipolar disorder.
In the United States, cenobamate is indicated for the treatment of partial-onset seizures in adults. [3]In the European Union, it is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medications.
Ad
related to: keppra xr duration of action in humans